title: A novel curcumin derivative increases the cytotoxicity of raloxifene in estrogen receptor-negative breast cancer cell lines.
abstract: There is a need for new, safe and efficacious drug therapies for the treatment of estrogen receptor (ER)-negative breast cancers. Raloxifene and the 2nd generation curcumin derivative 2,6-bis(pyridin-4-ylmethylene)-cyclohexanone (RL91) have been shown to inhibit the growth of ER-negative breast cancer cells in vitro and in vivo. We investigated whether RL91 could enhance the growth-suppressive effects mediated by raloxifene in MDA-MB-231, MDA-MB-468, Hs578t and SkBr3 human breast cancer cell lines. The cytotoxicity was consistent across the cell lines but RL91 was more potent. EC50 values for RL91 were 1.2-2 µM while EC50 values for raloxifene were 9.6-11.2 µM. When the cells were treated with raloxifene (15 µM), RL91 (1 µM) or a combination of the two for 6-72 h, the combination treatment consistently elicited significantly greater cytotoxicity compared to all other treatments. In SkBr3 cells the combination treatment caused significantly more cells to undergo G1 arrest compared to raloxifene. In all cell lines apoptosis was synergistically induced by the combination treatment, as shown by both flow cytometery and cleaved caspase-3. Furthermore, the stress kinase p38 was increased and EFGR isoforms were decreased by both raloxifene and raloxifene + RL91. The anti-angiogenic anti-metastatic potential of raloxifene was not increased by RL91, as MDA-MB-231 cell migration and invasion as well as endothelial tube formation by HUVEC cells was not different between raloxifene (10 µM) and the combination of raloxifene + RL91. Thus, our findings provide evidence that RL91 increases the ability of raloxifene to suppress ER-negative cancer cell growth by increasing the number of apoptotic cells. The broad effect of this drug combination across a range of ER-negative breast cancer cell lines indicates that this drug combination should be explored further in order to find a safe and efficacious therapy for ER-negative breast cancer.
authors.affiliation: Department of Pharmacology and Toxicology, University of Otago, Dunedin 9054, New Zealand.
authors.forename: Sebastien
authors.initials: S
authors.lastname: Taurin
authors.affiliation: Department of Pharmacology and Toxicology, University of Otago, Dunedin 9054, New Zealand.
authors.forename: Mhairi
authors.initials: M
authors.lastname: Nimick
authors.affiliation: Department of Chemistry, University of Otago, Dunedin 9054, New Zealand.
authors.forename: Lesley
authors.initials: L
authors.lastname: Larsen
authors.affiliation: Department of Pharmacology and Toxicology, University of Otago, Dunedin 9054, New Zealand.
authors.forename: Rhonda J
authors.initials: RJ
authors.lastname: Rosengren
mesh_terms: D017209:Apoptosis / Q000187:drug effects; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D053148:Caspase 3 / Q000378:metabolism; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D003474:Curcumin / Q000008:administration & dosage* / Q000031:analogs & derivatives; D004357:Drug Synergism; D005260:Female; D061307:Human Umbilical Vein Endothelial Cells; D006801:Humans; D009361:Neoplasm Invasiveness / Q000235:genetics / Q000473:pathology; D020849:Raloxifene Hydrochloride / Q000008:administration & dosage*; D011960:Receptors, Estrogen / Q000235:genetics; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D011960:Receptors, Estrogen; D020849:Raloxifene Hydrochloride; D053148:Caspase 3; D003474:Curcumin